ArticleJournal of ophthalmic inflammation and infection2025
Bilateral choroidal tuberculoma in a patient of miliary tuberculosis.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChoroidal granuloma is one of the common manifestations of ocular tuberculosis. Tubercles indicate hematogenous dissemination of the disease. Tubercular granulomas respond to Anti-Tubercular Treatment (ATT) and systemic corticosteroids. However, in some patients with large granulomas involving macula, adjunct treatment with intravitreal anti-VEGF may be required for prompt management of the granuloma.
findingsWe report a case of bilateral Tubercular granuloma in a patient with miliary Tuberculosis (TB). The patient was an immunocompetent young female with miliary tuberculosis. Mantoux was positive. HRCT chest suggested miliary TB. The patient was already on ATT. Clinical examination showed multiple TB granulomas in both eyes, with a large granuloma involving the fovea in the left eye. She underwent intravitreal injection of the anti-VEGF drug bevacizumab (1.25 mg/0.05 mL) (off-label use) with moxifloxacin (500 µg/0.1 mL) (off-label use) in the left eye. She was continued on ATT and was started on oral steroids. After seven weekly intravitreal injections in the left eye at the second-month follow-up, lesions were consolidated and scarred. Optical coherence tomography showed a decrease in the size of the choroidal bump.
conclusionWeekly administration of intravitreal Anti-Vascular endothelial growth factor(VEGF) and moxifloxacin, along with ATT and oral corticosteroids, has controlled inflammation and has caused consolidation and scarring of TB granulomas in a patient with miliary TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.